

**HOLD**

TP: Rs 193 | ▼ 2%

**STAR CEMENT**

| Cement

| 08 February 2024

### Cost savings commendable, growth intact

- Steady growth in a challenging quarter aided by 7% YoY volume pickup; realisations softened
- Cost savings of 8% YoY supported EBITDA margin gains of 530bps on a high base to ~23%
- TP raised to Rs 193 (vs. Rs 159) as we value STRCEM at 9x EV/EBITDA (vs. 8x) and roll over to FY26E; upside capped – retain HOLD

Milind Raginwar | Shree Kirloskar  
research@bobcaps.in

**Volumes fuel revenue, realisations weak:** STRCEM's revenue grew 5%/11% YoY/QoQ to Rs 6.5bn in Q3FY24 as volumes grew 7%/8% to 1mn tonnes. Realisations, however, fell 2% YoY (+3% QoQ) to Rs 6,716/t. Cement prices improved by Rs 7/bag in the northeast but dropped by ~Rs 20/bag in other regions at the end of the quarter.

**Operating cost declines:** Overall cost declined 8%/5% YoY/QoQ to Rs 5,182/t as energy cost adjusted for raw material inventory fell 10%/5% to Rs 2,666/t. Further, logistics costs softened 10% YoY but increased 13% QoQ to Rs 1,135/t. Other expenditure decreased 11% QoQ (flat YoY) to Rs 794mn.

**Lower cost aids margin expansion:** Bolstered by cost savings, EBITDA increased 37%/51% YoY/QoQ to Rs 1.5bn accompanied by margin expansion to 22.8% (+530bps/600bps). EBITDA/t rose to Rs 1,534 from Rs 1,194 in Q3FY23 (Rs 1,100 in Q2FY24) and adj. PAT grew 39%/81% YoY/QoQ to Rs 735mn.

**Capacity expansion plans:** The 2mt grinding unit in Guwahati, Assam, and 3mt clinker plant in Meghalaya are due to be commissioned by Q4FY24. Commencement of the Silchar grinding unit in Assam remains deferred to Q2FY26.

**Growth prospects intact...:** We raise our FY24 EPS estimate by 3% to reflect the Q3 print but keep FY25 unchanged (and now introduce FY26 forecasts). In our view, the government's infrastructure focus in STRCEM's core northeast market is likely to propel volumes even as a sound balance sheet despite being in capex mode should support ROE/ROCE expansion to an estimated 14%/19% by FY26. We thus assign a higher 9x EV/EBITDA multiple to the stock (vs. 8x earlier) while rolling valuations over to FY26E, which gives us a revised TP of Rs 193 (vs. Rs 159).

**...but upside capped, retain HOLD:** Current valuations of 11x/10x FY25E/FY26E EV/EBITDA cap upside potential and hence we maintain our HOLD rating. Our TP implies a replacement cost valuation of Rs 7.5bn/mt – in line with the industry average.

### Key changes

Target	Rating
▲	◀ ▶

Ticker/Price	STRCEM IN/Rs 196
Market cap	US\$ 1.0bn
Free float	33%
3M ADV	US\$ 1.6mn
52wk high/low	Rs 198/Rs 103
Promoter/FPI/DII	67%/1%/6%


Source: NSE | Price as of 8 Feb 2024

### Key financials

Y/E 31 Mar	FY23A	FY24E	FY25E
Total revenue (Rs mn)	25,756	32,869	40,705
EBITDA (Rs mn)	4,684	5,355	7,776
Adj. net profit (Rs mn)	2,477	2,767	4,138
Adj. EPS (Rs)	5.9	6.6	9.9
Consensus EPS (Rs)	5.9	6.4	9.1
Adj. ROAE (%)	10.8	10.9	14.6
Adj. P/E (x)	33.2	29.7	19.9
EV/EBITDA (x)	16.9	15.5	10.8
Adj. EPS growth (%)	0.4	11.7	49.5

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance



Source: NSE



**Fig 1 – Earnings call highlights**

Parameter	Q3FY24	Q2FY24	Our view
Volumes and Realisation	<p>Volumes for Q3FY24 stood at 1mt and management expects 8-10% growth in Q4FY24.</p> <p>Trade volume share stood at 87% and premium product sales formed ~6.5% of the mix. Management expects to double its current premium share in FY25.</p>	<p>Volumes for Q2FY24 stood at 0.9mt and management expects 13-14% growth for FY24.</p> <p>Trade volume share stood at ~89% and premium product sales formed ~6.9% of the mix. Management expects the premium share to reach ~10% by end-FY24.</p>	<p>We expect volumes to recover after the general elections given the government's focus on building up infrastructure in the northeast region.</p>
Margins	<p>Cement prices improved by Rs 7/bag in the northeast while dropping by ~Rs 20/bag in other regions at the end of Q3FY24. Management expects the status quo to be maintained in Q3.</p> <p>The fuel mix was ~12% FSA, 26% Nagaland coal, 7% biomass, and 55% spot option. Fuel cost stood at Rs 1.75/kcal while the lead distance was 215km.</p>	<p>Cement prices improved by ~Rs 10/bag in the northeast and ~Rs 50/bag in other regions at the end of Q2FY24, with the benefits likely to be visible in Q3. Only a slight rollback of Rs 5-7/bag is expected from the slowdown due to festivities.</p> <p>The fuel mix was ~6% FSA, 32% Nagaland coal, 5% biomass, and 57% spot option and trade purchase. Fuel cost stood at Rs 1.9/kcal while the lead distance was 214km.</p> <p>Margins were affected QoQ by a volume slowdown due to the monsoons and scheduled maintenance shutdown cost of ~Rs 150mn.</p>	<p>Cost saving initiatives and better capacity utilisation at Siliguri in West Bengal will likely aid margins.</p>
Capacity	<p>The 2mt Guwahati grinding unit and 3mt Meghalaya clinker plant are expected to be commissioned in Q4FY24. Commissioning of the 2mt Silchar grinding unit is due in Q2FY26</p>	<p>The 2mt Guwahati grinding unit is expected to be commissioned in Q3FY24 and the 3mt Meghalaya clinker plant in Q4FY24. Commissioning of the 2mt Silchar grinding unit has been strategically delayed till mid-FY25, although 73-75% of the land acquisition is complete.</p>	<p>In our view, Silchar capacity postponement is a good move strategically as staggering capacity addition will pay off.</p>
Capex	<p>Capex on the Guwahati plant till Q3FY24 was ~Rs 3.3bn and management expects an outlay of ~Rs 0.6bn for Q4 (against an aggregate internal target of ~Rs 4.3bn).</p> <p>Capex incurred on the Lumshnong plant totals ~Rs 8.5bn till Q3FY24, with ~Rs 2bn expected for Q4 (Rs 2bn more in Q1FY25).</p> <p>Capex on the Silchar plant stood at ~Rs 0.2bn as of Q3FY24.</p>	<p>Capex has been guided at ~Rs 8bn post Q1FY24, with ~Rs 2bn incurred during Q2. Guidance for FY25 is more than ~Rs 6bn, largely towards the Meghalaya clinker plant and Guwahati grinding unit. Capex on these projects during H1FY24 totalled ~Rs 7bn and ~Rs 2.1bn respectively.</p> <p>Management indicated that it may opt for debt of Rs 3bn in Q3-Q4 of FY24 to meet its capex target considering expected cash reserves of Rs 3.2bn for the fiscal year (Rs 2.1bn as on Q2FY24).</p>	<p>The company has managed capital expenditure well with minimum burden on the balance sheet.</p>
Other key points	<p>Incentives accrued during Q3FY24 amount to Rs 60mn from IGST benefits on the clinker plant.</p> <p>Management expects to receive SGST incentives amounting to Rs 1.5bn-1.6bn per annum for the next 5-6 years for setting up the new Guwahati grinding unit. It also expects IGST benefits on the 3.3mt clinker plant amounting to Rs 300/t of clinker produced till 2027.</p>	<p>The WHRS plant at Lumshnong, Meghalaya, has led to cost savings of ~Rs 100mn for STRCM. For its plans to reduce fly-ash landed cost at Siliguri, STRCEM is negotiating and ordering BTAP wagons and expects to have these in place by Q1FY25.</p> <p>Management indicated that STRCEM will commission a new clinker line one year before Dalmia Bharat and that competitive intensity after a year may lead to price corrections but will be made up by volume growth. The company is targeting 30%+ market share in the northeast.</p>	<p>Cost saving measures by STRCEM and better incentives for the new unit are likely to yield positive results over the medium term.</p>

Source: Company, BOBCAPS Research | BTAP: Bogy Tank Wagon for Alumina Powder; FSA: Fuel Supply Agreement; IGST: Integrated Goods and Services Tax; SGST: State Goods and Service Tax; WHRS: Waste Heat Recovery System

**Fig 2 – Key metrics**

(Rs)	Q3FY24	Q3FY23	YoY (%)	Q2FY24	QoQ (%)
Volumes (mt)	1.0	0.9	6.8	0.9	8.3
Cement realisations (Rs/t)	6,716	6,823	(1.6)	6,532	2.8
Operating costs (Rs/t)	5,182	5,629	(7.9)	5,432	(4.6)
EBITDA (Rs/t)	1,534	1,194	28.4	1,100	39.4


Source: Company, BOBCAPS Research

**Fig 3 – Quarterly performance**

(Rs mn)	Q3FY24	Q3FY23	YoY (%)	Q2FY24	QoQ (%)
<b>Net Sales</b>	<b>6,514</b>	<b>6,195</b>	<b>5.1</b>	<b>5,853</b>	<b>11.3</b>
<b>Expenditure</b>					
Change in stock	(308)	(349)	-	(105)	-
Raw material	1,558	1,440	8.2	1,300	19.8
Purchased products	0	0	0.0	0	0.0
Power & fuel	1,336	1,603	(16.6)	1,312	1.9
Freight	1,101	1,139	(3.4)	902	22.0
Employee costs	545	486	12.1	571	(4.5)
Other expenses	794	793	0.1	887	(10.5)
Total Operating Expenses	5,026	5,111	(1.7)	4,867	3.3
<b>EBITDA</b>	<b>1,488</b>	<b>1,084</b>	<b>37.2</b>	<b>986</b>	<b>50.9</b>
EBITDA margin (%)	22.8	17.5	534bps	16.8	600bps
Other Income	41	117	(64.8)	58	(28.4)
Interest	30	33	(10.2)	32	(8.7)
Depreciation	365	341	7.2	360	1.4
PBT	1,134	828	37.0	651	74.3
Non-recurring items	0	0	0.0	0	0.0
PBT (after non-recurring items)	1,134	828	37.0	651	74.3
Tax	399	299	33.4	244	63.5
Tax Rate (%)	35.2	36.1	(94bps)	37.5	(232bps)
Reported PAT	735	529	39.0	407	80.8
<b>Adjusted PAT</b>	<b>735</b>	<b>529</b>	<b>39.0</b>	<b>407</b>	<b>80.8</b>
NPM (%)	11.3	8.5	275bps	6.9	434bps
<b>Adjusted EPS (Rs)</b>	<b>1.8</b>	<b>1.3</b>	<b>42.9</b>	<b>1.0</b>	<b>80.8</b>


Source: Company, BOBCAPS Research

**Fig 4 – Volume growth picks up**




Source: Company, BOBCAPS Research

**Fig 5 – Realisation moves up sequentially**




Source: Company, BOBCAPS Research

**Fig 6 – Healthy recovery in EBITDA/tn**



Source: Company, BOBCAPS Research

**Fig 7 – Cost efficiencies look sustainable**




Source: Company, BOBCAPS Research

**Fig 8 – Higher logistics costs to ease with grinding unit commissioning**



Source: Company, BOBCAPS Research

**Fig 9 – Energy cost savings add further comfort**



Source: Company, BOBCAPS Research

## Valuation methodology

We raise our FY24 EPS estimate by 3% to reflect the Q3 print but keep FY25 unchanged (and now introduce FY26 forecasts). In our view, the government's infrastructure focus in STRCEM's core northeast market is likely to propel volume growth. The grinding unit in Guwahati will further consolidate the company's presence in Assam and the northeast region. Moreover, we believe the company's plans to derisk revenue, likely improvement in Siliguri unit utilisation once the Meghalaya clinker unit is commissioned in Q4FY24 and a sound balance sheet despite being in capex mode will support ROE/ROCE expansion to an estimated 14%/19% by FY26.

Factoring in the same, we assign a higher 9x EV/EBITDA multiple to the stock (vs. 8x earlier) while rolling valuations over to FY26E, which gives us a revised TP of Rs 193 (vs. Rs 159). However, current valuations of 11x/10x FY25E/FY26E EV/EBITDA cap upside potential and hence we maintain our HOLD rating. Our TP implies a replacement cost valuation of Rs 7.5bn/mt – in line with the industry average.

**Fig 10 – Revised estimates**

(Rs mn)	New			Old			Change (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	32,869	40,705	48,361	32,869	40,504	NA	0.0	0.5	NA
EBITDA	5,355	7,776	8,631	5,355	7,492	NA	0.0	3.8	NA
Adj PAT	2,767	4,138	4,591	2,688	4,147	NA	2.9	(0.2)	NA
Adj EPS (Rs)	6.6	9.9	11.0	6.4	9.9	NA	3.1	0.0	NA

Source: BOBCAPS Research

**Fig 11 – Key assumptions**

Parameter	FY23	FY24E	FY25E	FY26E
Volumes (mt)	3.30	3.80	4.56	5.65
Realisations (Rs/t)	6,767	6,970	7,004	6,847
Operating costs (Rs/t)	5,885	6,042	5,831	5,761
EBITDA/t (Rs/t)	1,233	1,166	1,368	1,244

Source: Company, BOBCAPS Research

**Fig 12 – Valuation summary**

(Rs mn)	FY26E
Target EV/EBITDA (x)	9.0
EBITDA	8,631
Target EV	79,839
Total EV	79,839
Net debt	1,779
Target market capitalisation	78,061
<b>Target price (Rs/sh)</b>	<b>193</b>
Weighted average shares (mn)	404


Source: BOBCAPS Research

**Fig 13 – Peer comparison**

Ticker	Rating	TP (Rs)	EV/EBITDA (x)			EV/tonne (US\$)			ROE (%)			ROCE (%)		
			FY23	FY24E	FY25E	FY23	FY24E	FY25E	FY23	FY24E	FY25E	FY23	FY24E	FY25E
STRCEM IN	HOLD	193	16.9	15.5	10.8	110	123	113	10.8	10.9	14.6	16.9	14.7	19.5
ORCMNT IN	SELL	168	16.5	13.3	11.5	43	41	39	7.9	10.4	12.7	10.5	12.8	13.7
JKLC IN	SELL	551	10.1	9.5	8.7	81	84	93	12.8	13.4	14.4	16.2	17.3	17.2


Source: BOBCAPS Research

**Fig 14 – EV/EBITDA band: Stock rerating well-deserved**




Source: Company, BOBCAPS Research

**Fig 15 – EV/EBITDA 1Y fwd**




Source: Company, BOBCAPS Research

**Fig 16 – EV/tonne: Expect replacement cost value to move up in the medium term**



Source: Company, BOBCAPS Research

**Fig 17 – EV/tonne 1Y fwd**



Source: Company, BOBCAPS Research

### Key risks

- Strong demand revival in the northeast and further cost relief contributed by easing energy prices are key upside risks to our estimates.
- Fierce competitive pressure from companies in the eastern region can strain pricing, representing a downside risk to our estimates.

### Sector recommendation snapshot

Company	Ticker	Market Cap (US\$ bn)	Price (Rs)	Target (Rs)	Rating
ACC	ACC IN	5.7	2,511	2,542	HOLD
Ambuja Cements	ACEM IN	13.6	563	552	HOLD
Dalmia Bharat	DALBHARA IN	4.7	2,100	2,443	HOLD
JK Cement	JKCE IN	4.0	4,214	4,121	HOLD
JK Lakshmi Cement	JKLC IN	1.3	917	551	SELL
Orient Cement	ORCMNT IN	0.7	267	168	SELL
Shree Cement	SRCM IN	12.0	27,370	27,836	HOLD
Star Cement	STRCEM IN	1.0	196	193	HOLD
The Ramco Cements	TRCL IN	2.8	974	661	SELL
Ultratech Cement	UTCEN IN	35.1	9,998	11,510	BUY

Source: BOBCAPS Research, NSE | Price as of 8 Feb 2024

## Financials

### Income Statement

Y/E 31 Mar (Rs mn)	FY22A	FY23A	FY24E	FY25E	FY26E
<b>Total revenue</b>	<b>20,902</b>	<b>25,756</b>	<b>32,869</b>	<b>40,705</b>	<b>48,361</b>
EBITDA	3,453	4,684	5,355	7,776	8,631
Depreciation	(1,216)	(1,311)	(1,508)	(1,784)	(2,026)
EBIT	2,570	3,894	4,114	6,308	6,753
Net interest inc./(exp.)	(133)	(96)	(120)	(242)	(213)
Other inc./(exp.)	334	521	267	316	148
Exceptional items	0	0	0	0	0
EBT	2,437	3,798	3,994	6,066	6,540
Income taxes	31	(1,321)	(1,226)	(1,928)	(1,948)
Extraordinary items	0	0	0	0	0
Min. int./Inc. from assoc.	0	0	0	0	0
<b>Reported net profit</b>	<b>2,468</b>	<b>2,477</b>	<b>2,767</b>	<b>4,138</b>	<b>4,591</b>
Adjustments	0	0	0	0	0
<b>Adjusted net profit</b>	<b>2,468</b>	<b>2,477</b>	<b>2,767</b>	<b>4,138</b>	<b>4,591</b>

### Balance Sheet

Y/E 31 Mar (Rs mn)	FY22A	FY23A	FY24E	FY25E	FY26E
Accounts payables	1,146	2,820	2,793	3,342	4,032
Other current liabilities	4,501	3,972	4,369	5,024	5,778
Provisions	66	97	91	100	110
Debt funds	54	261	5,057	3,157	2,557
Other liabilities	0	0	0	0	0
Equity capital	404	404	404	404	404
Reserves & surplus	21,280	23,760	26,070	29,748	33,875
Shareholders' fund	21,684	24,164	26,475	30,152	34,280
<b>Total liab. and equities</b>	<b>27,451</b>	<b>31,314</b>	<b>38,784</b>	<b>41,776</b>	<b>46,757</b>
Cash and cash eq.	3,847	3,117	4,184	1,378	1,680
Accounts receivables	1,287	1,047	1,936	2,342	2,716
Inventories	1,953	3,741	2,882	3,346	3,975
Other current assets	4,863	4,377	4,466	4,511	4,556
Investments	1,637	1,725	1,637	1,637	1,637
Net fixed assets	9,225	8,850	19,579	23,141	25,820
CWIP	1,091	5,506	859	1,859	2,459
Intangible assets	10	60	62	64	67
Deferred tax assets, net	3,539	2,890	3,179	3,497	3,847
Other assets	0	0	0	0	0
<b>Total assets</b>	<b>27,451</b>	<b>31,314</b>	<b>38,784</b>	<b>41,776</b>	<b>46,757</b>

### Cash Flows

Y/E 31 Mar (Rs mn)	FY22A	FY23A	FY24E	FY25E	FY26E
<b>Cash flow from operations</b>	<b>4,333</b>	<b>4,543</b>	<b>4,231</b>	<b>5,903</b>	<b>6,673</b>
Capital expenditures	(1,959)	(5,394)	(7,593)	(6,348)	(5,307)
Change in investments	(1,620)	(89)	89	0	0
Other investing cash flows	0	0	0	0	0
<b>Cash flow from investing</b>	<b>(3,579)</b>	<b>(5,482)</b>	<b>(7,505)</b>	<b>(6,348)</b>	<b>(5,307)</b>
Equities issued/Others	420	422	0	0	0
Debt raised/repaid	(99)	207	4,796	(1,900)	(600)
Interest expenses	7	8	9	10	10
Dividends paid	(419)	(419)	(419)	(419)	(419)
Other financing cash flows	(1,525)	-	(37)	(41)	(45)
<b>Cash flow from financing</b>	<b>(1,624)</b>	<b>210</b>	<b>4,340</b>	<b>(2,360)</b>	<b>(1,064)</b>
<b>Chg in cash &amp; cash eq.</b>	<b>(870)</b>	<b>(729)</b>	<b>1,066</b>	<b>(2,805)</b>	<b>301</b>
<b>Closing cash &amp; cash eq.</b>	<b>3,847</b>	<b>3,118</b>	<b>4,184</b>	<b>1,378</b>	<b>1,680</b>

### Per Share

Y/E 31 Mar (Rs)	FY22A	FY23A	FY24E	FY25E	FY26E
Reported EPS	5.9	5.9	6.6	9.9	11.0
Adjusted EPS	5.9	5.9	6.6	9.9	11.0
Dividend per share	1.0	1.0	1.0	1.0	1.0
Book value per share	51.7	57.6	63.2	71.9	81.8

### Valuations Ratios

Y/E 31 Mar (x)	FY22A	FY23A	FY24E	FY25E	FY26E
EV/Sales	3.8	3.1	2.5	2.1	1.7
EV/EBITDA	22.7	16.9	15.5	10.8	9.4
Adjusted P/E	33.3	33.2	29.7	19.9	17.9
P/BV	3.8	3.4	3.1	2.7	2.4

### DuPont Analysis

Y/E 31 Mar (%)	FY22A	FY23A	FY24E	FY25E	FY26E
Tax burden (Net profit/PBT)	101.3	65.2	69.3	68.2	70.2
Interest burden (PBT/EBIT)	94.8	97.5	97.1	96.2	96.8
EBIT margin (EBIT/Revenue)	12.3	15.1	12.5	15.5	14.0
Asset turnover (Rev./Avg TA)	78.8	87.7	93.8	101.1	109.3
Leverage (Avg TA/Avg Equity)	1.3	1.3	1.4	1.4	1.4
<b>Adjusted ROAE</b>	<b>11.6</b>	<b>10.8</b>	<b>10.9</b>	<b>14.6</b>	<b>14.3</b>

### Ratio Analysis

Y/E 31 Mar	FY22A	FY23A	FY24E	FY25E	FY26E
<b>YoY growth (%)</b>					
Revenue	21.6	23.2	27.6	23.8	18.8
EBITDA	3.8	35.7	14.3	45.2	11.0
Adjusted EPS	(2.0)	0.4	11.7	49.5	11.0
<b>Profitability &amp; Return ratios (%)</b>					
EBITDA margin	15.5	17.3	16.3	19.1	17.8
EBIT margin	11.6	14.4	12.5	15.5	14.0
Adjusted profit margin	11.8	9.6	8.4	10.2	9.5
Adjusted ROAE	11.6	10.8	10.9	14.6	14.3
ROCE	12.1	16.9	14.7	19.5	19.3
<b>Working capital days (days)</b>					
Receivables	22	15	22	21	21
Inventory	34	53	32	30	30
Payables	22	46	37	37	37
<b>Ratios (x)</b>					
Gross asset turnover	1.4	1.6	1.1	1.2	1.2
Current ratio	2.1	1.8	1.9	1.4	1.3
Net interest coverage ratio	19.3	40.6	34.2	26.1	31.7
<b>Adjusted debt/equity</b>	<b>0.0</b>	<b>0.0</b>	<b>0.2</b>	<b>0.1</b>	<b>0.1</b>

Source: Company, BOBCAPS Research | Note: TA = Total Assets

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

## Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

**Recommendation scale: Recommendations and Absolute returns (%) over 12 months**

**BUY** – Expected return >+15%

**HOLD** – Expected return from -6% to +15%

**SELL** – Expected return <-6%

**Note:** Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

### Ratings and Target Price (3-year history): STAR CEMENT (STRCEM IN)



B – Buy, H – Hold, S – Sell, A – Add, R – Reduce

#### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

#### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

#### **Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014**

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### **Other disclaimers**

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an “as is” basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS’s judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the “Losses”) which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### **Distribution into the United Kingdom (“UK”):**

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd (“MSL”) who is authorised and regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom (MSL and its affiliates are collectively referred to as “MAYBANK”). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK’s legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the “Order”), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as “relevant persons”).

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### **No distribution into the US:**

This report will not be distributed in the US and no US person may rely on this communication.

#### **Other jurisdictions:**

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.